David Vaughan

has over 25 years of broad pharmaceutical development experience. Since 2001, he has acted as an independent consultant to the pharmaceutical industry with significant clinical/ preclinical development and regulatory expertise in the GI, infectious disease, pain and CNS areas.

More broadly, Dr. Vaughan has led or participated in numerous pre-clinical and NDA submission activities across virtually all therapeutic areas for numerous well known large pharmaceutical and venture-stage biotechnology companies. His past employers or clients include: BMS, Bayer, Pfizer, Affinium, NeurAxon, Intermune, Oscient, and Replidyne and he has also been an Entrepreneur-in-Residence at the University of Toronto.

Prior to entering industry, Dr. Vaughan conducted oncology research at The Princess Margaret Hospital in Toronto.  He received his PhD in Clinical Pathology and Biochemistry from the University of Toronto.